The following is a summary of the Know Labs, Inc. (KNW) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Know Labs reported an operating loss of $4.73 million for Q2 2024, a decrease of 1.7% from the same period in the previous year.

• Earnings per share improved to a loss of $0.07, compared to a loss of $0.10 per share last year.

• Research and development expenses decreased by 15.1% to $2.18 million, while selling, general, and administrative expenses increased by 13.7% to $2.55 million.

• As of Q2 2024, the company had $4.71 million in cash and cash equivalents.

Business Progress:

• Know Labs has successfully developed and tested the KnowU, a wearable, non-invasive, continuous glucose monitoring device.

• Completed an internal trial with over 30 participants showing a Mean Absolute Relative Difference (MARD) of 11.1%.

• Holds over 300 patents issued, pending, and in process.

• Secured a funding agreement of up to $12 million from Lind Global Fund II LP.

• Aims to raise equity capital from long-term investors and is committed to avoiding structured finance that might harm current investors.

• The company has appointed Chris Somogyi as President International, focusing on international markets and monetization of the company's intellectual property.

• Initiated the FDA process for its technology and aims to hold a pre-submission meeting with the FDA during fiscal year '24.

More details: Know Labs IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.